Moreover, the data suggested an immune influence of T-DXd treatment in HER2 low-expressing breast cancer, which suggests different mechanisms of action of T-DXd treatment that depend on HER2 expression in breast cancer. This evidence concerns the gene ERBB2 and breast cancer.